CA2269097A1 - Synthesis and purification of hepatitis c virus-like particles - Google Patents

Synthesis and purification of hepatitis c virus-like particles

Info

Publication number
CA2269097A1
CA2269097A1 CA002269097A CA2269097A CA2269097A1 CA 2269097 A1 CA2269097 A1 CA 2269097A1 CA 002269097 A CA002269097 A CA 002269097A CA 2269097 A CA2269097 A CA 2269097A CA 2269097 A1 CA2269097 A1 CA 2269097A1
Authority
CA
Canada
Prior art keywords
particles
virus
hepatitis
purification
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002269097A
Other languages
French (fr)
Other versions
CA2269097C (en
Inventor
T. Jake Liang
Thomas F. Baumert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services
T. Jake Liang
Thomas F. Baumert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services, T. Jake Liang, Thomas F. Baumert filed Critical The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services
Publication of CA2269097A1 publication Critical patent/CA2269097A1/en
Application granted granted Critical
Publication of CA2269097C publication Critical patent/CA2269097C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle

Abstract

Production of enveloped RNA
virus-like particles intracellularly in vitro in insect cells using a recombinant baculovirus vector containing a cDNA coding for viral structural proteins is disclosed. In vitro production and purification of hepatitis C virus (HCV)-like particles containing HCV
core protein, E1 protein and E2 protein is disclosed. Production of antibodies in vivo to the purified HCV-like particles is disclosed.
CA002269097A 1996-11-08 1997-03-25 Synthesis and purification of hepatitis c virus-like particles Expired - Fee Related CA2269097C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3023896P 1996-11-08 1996-11-08
US60/030,238 1996-11-08
PCT/US1997/005096 WO1998021338A1 (en) 1996-11-08 1997-03-25 Synthesis and purification of hepatitis c virus-like particles

Publications (2)

Publication Number Publication Date
CA2269097A1 true CA2269097A1 (en) 1998-05-22
CA2269097C CA2269097C (en) 2007-01-09

Family

ID=21853241

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002269097A Expired - Fee Related CA2269097C (en) 1996-11-08 1997-03-25 Synthesis and purification of hepatitis c virus-like particles

Country Status (8)

Country Link
US (1) US6387662B1 (en)
EP (1) EP0941337B1 (en)
JP (2) JP4021493B2 (en)
AT (1) ATE423204T1 (en)
AU (1) AU738585B2 (en)
CA (1) CA2269097C (en)
DE (1) DE69739268D1 (en)
WO (1) WO1998021338A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO1999067394A1 (en) * 1998-06-24 1999-12-29 Chugai Seiyaku Kabushiki Kaisha Vector expressing the full-length gene of rna virus and use thereof
IL140217A0 (en) * 1998-06-24 2002-02-10 Innogenetics Nv Particles of hcv envelope proteins: use for vaccination
US6849429B1 (en) * 1999-11-19 2005-02-01 Board Of Regents, The University Of Texas System Viral pseudo-capsids including assembly agonists and antagonists
JP2002030098A (en) * 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd Method for recovering virion envelope from budded virus of baculovirus
FR2814755B1 (en) * 2000-09-29 2002-11-29 Agronomique Inst Nat Rech PRODUCTION OF PSEUDOVIRAL HCV PARTICLES IN INSECT CELLS
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030021805A1 (en) * 2001-05-29 2003-01-30 Barber Glen N. Generation of HCV-like particles and chimeric HCV virus
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
GB0215617D0 (en) * 2002-07-08 2002-08-14 Univ Leeds Use of hepatitis C virus (HCV) p7 protein
ES2327039T3 (en) 2002-09-13 2009-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) INFECTIOUS HEPACIVIRUS PSEUDOPARTICLES CONTAINING PROTEINS OF THE WRAPPER E1, E2.
EP1742963A2 (en) * 2004-05-04 2007-01-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Synthesis and purification of west nile virus virus-like particles
JP2008500364A (en) * 2004-05-25 2008-01-10 キメラコア， インコーポレイテッド Self-assembling nanoparticle drug delivery system
DE602005026545D1 (en) * 2004-08-24 2011-04-07 Tokyo Metropolitan Org Med Res MODIFIED HUMAN HEPATITIS C-VIRUS GENOMIC RNA WITH AUTONOMIC REPLICATION COMPETENCE
CU23496A1 (en) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech VACCINE COMPOSITION AGAINST THE VIRUS OF HEPATITIS C
WO2006038129A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Srl Hepatitis c virus replication system
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
AU2007348315A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating B- cell malignancies
WO2007128048A1 (en) * 2006-05-02 2007-11-15 The Macfarlane Burnet Institute For Medical Research And Public Health Limited A hepatitis c vaccine delivery vehicle
WO2007144886A2 (en) 2006-06-15 2007-12-21 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
CA2678888C (en) 2007-02-21 2015-04-14 University Of Massachusetts Human antibodies against hepatitis c virus (hcv) and uses thereof
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Virus like particle purification
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
JPWO2011040535A1 (en) 2009-09-30 2013-02-28 東レ株式会社 Hepatitis C virus vaccine composition
JP2014527072A (en) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． Methods and compositions for controlling the assembly of viral proteins
JOP20130186B1 (en) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc Purification of virus like particles
JP6427100B2 (en) 2012-08-31 2018-11-21 ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ Methods and compositions for producing cells having a primary human hepatocyte phenotype
JP2015015931A (en) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ Method for producing culture comprising virus-like particles
US10188710B2 (en) * 2013-11-04 2019-01-29 Rhode Island Council On Postsecondary Education Regulatory T cell epitope and hepatitis C virus homolog
US11154614B2 (en) 2016-04-22 2021-10-26 Integrated Research Associates, Llc Method for producing virus like particles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (en) 1967-05-23 1971-08-02 Pharmacia Ab
DE3445816C1 (en) 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flat diagnostic agent
US4956302A (en) 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
DE3887491T2 (en) 1987-12-21 1994-07-07 Abbott Lab Chromatographic binding assay devices and methods.
ATE161041T1 (en) 1989-08-25 1997-12-15 Chiron Corp METHOD FOR CULTIVATION OF HCV IN CELL LINES FROM B OR T LYMPHOCYTES
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
SK286106B6 (en) 1990-11-08 2008-03-05 Novartis Vaccines & Diagnostics, Inc. An immunoassay method for detecting an antibody against hepatitis C virus
WO1993006126A1 (en) 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
KR0172970B1 (en) * 1992-06-17 1999-02-01 김영길 Chimeric proteins useful for an aids vaccine and the preparation thereof
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay

Also Published As

Publication number Publication date
ATE423204T1 (en) 2009-03-15
EP0941337B1 (en) 2009-02-18
EP0941337A1 (en) 1999-09-15
CA2269097C (en) 2007-01-09
AU2347997A (en) 1998-06-03
JP4231083B2 (en) 2009-02-25
WO1998021338A1 (en) 1998-05-22
JP2001504337A (en) 2001-04-03
DE69739268D1 (en) 2009-04-02
JP2007300934A (en) 2007-11-22
AU738585B2 (en) 2001-09-20
US6387662B1 (en) 2002-05-14
JP4021493B2 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
CA2269097A1 (en) Synthesis and purification of hepatitis c virus-like particles
IL115578A0 (en) Production of peptides in plants as viral coat protein fusions
CA2220575A1 (en) Soluble, active hepatitis c virus protease
DK0809700T3 (en) Papillomavirus-like particles, fusion proteins, and their method of preparation
CA2189882A1 (en) Papillomavirus vaccines
CA2171699A1 (en) Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell
EP0484787A3 (en) Hcv-specific peptides, process for obtaining them and their use
WO1994003620A3 (en) Method of increasing expression of viral proteins
DE122007000015I2 (en) Method for in vitro disassembly and reassembly of papillomavirus virus-like particles (vlps)
CA2110058A1 (en) Hepatitis c virus (hcv) polypeptides
WO1995012677A3 (en) Immunodominant human t-cell epitopes of hepatitis c virus
CA2178752A1 (en) N-Terminally Chemically Modified Protein Compositions and Methods
AU1365788A (en) Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
CA2400295A1 (en) Modified factor viii
CA2104396A1 (en) Viral particles having altered host range
WO2000006717A3 (en) Improved transformation efficiency in phage display through modification of a coat protein
GB8819453D0 (en) Production of bluetongue virus non-structural proteins using baculovirus expression vector
CA2320488A1 (en) Strategically modified hepatitis b core proteins and their derivatives
CA2092680A1 (en) Epstein-barr virus sequences and protein thereof
NO304380B1 (en) Process for the preparation of a hepatitis C virus (HCV) asialoglycoprotein
DE69841015D1 (en) INTRA-CELLULAR PREPARATION OF SHORTENED HEPATITIS C POLYPEPTIDE E2
HUT60772A (en) Process for producing non-a, non-b hepatitis virus genomial cdna and antigen polypeptide
CA2162557A1 (en) Conserved motif of hepatitis c virus e2/ns1 region
HUT45559A (en) Process for producing new proteines and peptides of antigene activity and vaccines against virus of infective gastritis-enteritis
JP2646013B2 (en) Antiviral agent

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150325